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Abstract
Background: Since 2003, a marked increase in leptospirosis serogroup Australis has
been observed in dogs in Switzerland. In 2013, a new quadrivalent antileptospiral
vaccine (L4) was introduced, adding serogroups Australis and Grippotyphosa to Can-
icola and Icterohaemorrhagiae of the previous bivalent vaccines (L2).
Objective: To examine whether introduction of L4 was associated with decreased
incidence of leptospirosis and decreased odds for dogs with acute kidney injury (AKI)
to be diagnosed with leptospirosis.
Animals: Four hundred and sixty-nine dogs with AKI presented to a referral hospital,
including 269 dogs with leptospirosis and 200 controls with other causes.
Methods: Descriptive section: disease incidence was evaluated for 3 consecutive
periods: before (PRE, 2011-2012), transition (TRANS, 2013-2014), and after intro-
duction of L4 (POST, 2015-2017). Analytical section: variables associated with a diag-
nosis of leptospirosis were investigated in a case-control study using multivariable
logistic regression, and focusing on vaccination.
Results: The number of dogs diagnosed with leptospirosis (AKI-L) decreased from
56.5 (PRE) to 15.7 (POST) cases/year while controls increased from 16.5 to 38.0
cases/year. Control dogs (AKI-nL) showed a decrease in L2 vaccination (100% to
26%) and an increase in L4 vaccination (0% to 70%). The odds ratio for vaccinated
dogs to be diagnosed with leptospirosis was 0.11 (95% confidence interval [CI],
0.06-0.22; P < .001) for L4 and 2.08 (0.58-7.42; P = .26) for L2.
Conclusions and Clinical Importance: The introduction of L4 was associated with a
marked decrease in dogs with leptospirosis and AKI in Switzerland. Use of the L4 vac-
cine was associated with significantly decreased odds of disease.
Abbreviations: AIC, Akaike Information Criterion; AKI, acute kidney injury; AKI-L, acute kidney injury due to leptospirosis; AKI-nL, acute kidney injury not due to leptospirosis; IQR, interquartile
range; L, leptospirosis; L2, bivalent antileptospiral vaccine; L4, quadrivalent antileptospiral vaccine; MAT, microscopic agglutination test; OR, odds ratio; ROC-AUC, area under the receiver
operating characteristic curve; RT-PCR, reverse transcriptase polymerase chain reaction.
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1 | INTRODUCTION
Leptospirosis is a zoonotic disease with worldwide distribution affect-
ing most mammalian species, including humans and dogs.1,2 It is cau-
sed by infection with pathogenic Leptospira spp., which colonize the
renal tubules of chronically infected hosts and are shed into the envi-
ronment via urine. Maintenance hosts infected with host-adapted Lep-
tospira spp. typically are asymptomatic whereas incidental hosts can
suffer a wide range of clinical manifestations including fever, kidney
and liver injury, systemic and pulmonary hemorrhage, and reproduc-
tive failure.3-7 Dogs have been known to be susceptible to acute lep-
tospiral infection for over 80 years,8 and serovars belonging to
serogroups Canicola and Icterohaemorrhagiae have been thought until
recently to be the main cause of clinical leptospirosis in dogs.5 Biva-
lent whole cell vaccines including serovars belonging to serogroups
Canicola and Icterohaemorrhagiae have been available in Europe since
the 1960s.9 These bivalent vaccines confer only partial or no immu-
nity to heterologous serogroups such as Australis, Grippotyphosa and
Pomona, which have been shown to cause acute disease in dogs.10,11
After approximately 30 years of only occasional disease in Swit-
zerland, the period between 2003 and 2012 was characterized by a
25-fold increase in the number of cases of clinically manifested acute
leptospirosis in dogs diagnosed at a veterinary teaching hospital,
exceeding the incidence in other European countries.4 The main clini-
cal manifestations of this re-emerging epidemic of leptospirosis in
dogs in Switzerland often were severe and included acute kidney
injury (AKI, 99%), acute liver injury (26%), hemorrhagic tendencies
(18%), and leptospiral pulmonary hemorrhage syndrome (77%).
Approximately 70% of dogs in this cohort showed serologic evidence
of infection with serovars Bratislava and Australis, both belonging to
serogroup Australis.4
In 2013, a new quadrivalent antileptospiral vaccine (Nobivac
Lepto 6, MSD Animal Health, also known as Nobivac L4 in other
countries; L4) was introduced onto the Swiss market.12 This killed
whole cell vaccine includes serovars of serogroups Australis and
Grippotyphosa in addition to serogroups Canicola and
Icterohaemorrhagiae present in the previously available bivalent vac-
cines (L2). The vaccine had been shown to provide excellent protec-
tion against experimental challenge of dogs with heterologous strains
from the same serogroups.12 Because of effective marketing and con-
tinuous education efforts by specialists working in academia, the
uptake of this vaccine in Switzerland appeared to be quick, providing
the unique opportunity to study the change in epidemiology of lepto-
spirosis in dogs associated with the change in prevention.
Therefore, the aims of our retrospective case-control study were
to describe the changes in numbers of cases of AKI in dogs with
causal evidence of leptospirosis (AKI-L) over a 7-year period
(2011-2017) compared to a control group of similarly affected dogs
with AKI not caused by leptospirosis (AKI-nL), and to investigate
vaccination-related variables associated with a diagnosis of
leptospirosis.
2 | MATERIALS AND METHODS
2.1 | Study design
The study was divided into 2 sections. The descriptive section was
designed to report the incidences of AKI-L and AKI-nL in dogs pres-
ented to a veterinary teaching hospital. The incidences were evalu-
ated in 3 consecutive time periods, spanning 2 years before
introduction of the L4 vaccine (PRE, 2011-2012), a transition period
of 2 years during progressive uptake of the vaccine by practitioners
(TRANS, 2013-2014), and a 3-year postintroduction period (POST,
2015-2017). An analytical section was designed as a retrospective
case-control study to evaluate variables associated with a diagnosis of
leptospirosis, focusing on antileptospiral vaccination status.13 For the
case-control study, a case was defined as a dog diagnosed with AKI
caused by leptospirosis (AKI-L). A control was defined as a dog diag-
nosed with AKI of other causes (AKI-nL). This control population was
chosen because it consists of dogs with similar clinical presentation
and disease severity diagnosed during the same time.
2.2 | Case definitions, diagnoses, inclusion, and
exclusion criteria
All dogs diagnosed with AKI at the referral Small Animal Clinic of the
Vetsuisse Faculty University of Bern between 2011 and 2017 were
included in the study if they met the diagnostic criteria for either lep-
tospirosis (AKI-L) or control (AKI-nL). Dogs presented for >1 episode
of AKI only were included the first time. This total population of dogs
diagnosed with AKI-L and AKI-nL formed the basis for the description
of the disease and of the case numbers, independently of the avail-
ability of vaccination information. Only dogs with a complete vaccina-
tion history available from the medical records or retrievable
retrospectively by contacting the owners or the referring veterinarians
were included in the evaluation of a potential association between
antileptospiral vaccination status and diagnosis of AKI-L.
Acute kidney injury was defined by the combination of historical,
clinical, laboratory, and imaging evidence, with at least 2 of the follow-
ing criteria14: (a) presence of renal azotemia with a serum creatinine
concentration ≥ 1.7 mg/dL persisting at least 24 hours after correc-
tion of prerenal factors; (b) increase in serum creatinine concentration
≥0.3 mg/dL during a 48-hour interval in the absence of prerenal fac-
tors; (c) persistent pathological oligo-anuria (<1 mL/kg/h over 6 hours)
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after volume repletion; (d) and evidence of tubular injury with renal
glucosuria or granular casts on urinalysis. Dogs with evidence of
underlying chronic kidney disease were not excluded from the study,
as long as they fulfilled the criteria for AKI.
2.3 | Acute kidney injury due to leptospirosis
(AKI-L)
A suspicion of leptospirosis was based on compatible clinical find-
ings indicative of an inflammatory syndrome (fever, muscle pain,
reluctance to move), gastrointestinal disturbances (anorexia,
abdominal pain, vomiting, diarrhea), hemostatic disturbances (pete-
chiae, ecchymoses), renal involvement (oligo-anuria, polyuria, fluid
disturbances, hematuria, uremic odor, oral ulcerations), liver
involvement (icterus), or pulmonary involvement (tachypnea, dys-
pnea, increased lung sounds including crackles). The suspicion was
confirmed by the presence of at least 1 of the following, in order
of preference: positive urine or tissue real-time reverse transcrip-
tase polymerase chain reaction (RT-PCR) 1a); a microagglutination
test (MAT) seroconversion with at least 4-fold titer increase (1b); a
single positive MAT titer ≥1:800 (1c); a single positive IgM lateral
flow assay (1d); strong clinical evidence with at least 3 of the
4 classical organ manifestations of leptospirosis (renal, hepatic,
pulmonary, hemorrhagic; 1e); or suggestive clinical evidence with
2 of the 4 organ manifestations (1f ) in the absence of another
cause. The last 2 criteria (1e and 1f ) only were considered in cases
in which leptospirosis could not be confirmed serologically
because of early death.
2.4 | Acute kidney injury not due to leptospirosis
(AKI-nL)
Control dogs were diagnosed and confirmed with AKI-nL based on
a known alternative diagnosis (2a) or a suspicion of a cause other
than leptospirosis with negative paired MAT serology (2b). A ten-
tative diagnosis of AKI-nL was considered for dogs with a suspi-
cion of AKI-nL and 1 negative MAT serology (2c), and for dogs
without evidence of leptospirosis in which no cause was positively
identified (2d).
2.5 | Confirmatory testing
The MAT testing was performed by the National Reference Labo-
ratory for Leptospirosis, Institute of Veterinary Bacteriology,
Vetsuisse Faculty University of Bern and was conducted using a
panel of 12-13 serovars, including L. interrogans serovars Australis,
Autumnalis, Bataviae, Bratislava, Canicola, Copenhageni (added to
the panel in 2015), Hardjo, Icterohaemorrhagiae, Pomona,
Pyrogenes, Sejroe, and Tarassovi, and L. kirschneri serovar
Grippotyphosa.
2.6 | Vaccine use and vaccination status
Antileptospiral vaccination records were considered complete if
they included the type of vaccine used (L2 or L4), as well as docu-
mentation of the initial vaccination consisting of 2 injections, of
the individual boosters, and of the last vaccine. Lack of vaccination
was differentiated from lack of recording by a thorough review of
the dog's health maintenance booklet in which all vaccines are offi-
cially recorded. When a gap in health maintenance was observed,
it was double-checked by consulting the medical records of the
referring veterinarian or by interviewing the dog's owners. Dogs
with incomplete or doubtful records were excluded from the
analyses.
Vaccine use was defined as the last vaccine type used in a defined
dog before AKI diagnosis. In this respect, dogs were classified as
either nonvaccinated (L0) if they had never received any anti-
leptospiral vaccine, or vaccinated with either a bivalent vaccine (L2,
serogroups Canicola and Icterohaemorrhagiae) or a quadrivalent vac-
cine (L4, serogroups Canicola, Icterohaemorrhagiae, Australis, and
Grippotyphosa). Although dogs vaccinated with L4 technically also
were immunized against the 2 serovars contained in L2, these dogs
were considered L4 and not L2 vaccinated.
Based on their antileptospiral vaccination status, dogs were
classified in 1 of 5 categories: nonvaccinated (L0), partially vacci-
nated with L2 (L2−), partially vaccinated with L4 (L4−), adequately
vaccinated with L2 (L2+) or adequately vaccinated with L4 (L4+).
The L2 and L4 vaccination status was considered adequate (L2+ or
L4+) if the dogs had received the initial 2 injections at an interval
of 20-30 days, followed by yearly boosters (maximum interval of
18 months), and if the last injection was at most 365 days before
the first clinical signs attributable to leptospirosis or AKI. Dogs
were considered vaccinated with claim for protection starting
10 days after completion of the initial 2 injections. These criteria
were based on pathophysiological justification of the expected
immune response, clinical observations of humans and dogs with
naturally occurring disease, and unpublished observations from the
vaccine manufacturer.2,12 When ≥1 of these criteria were not ful-
filled in vaccinated dogs, vaccination status was considered partial
or inadequate (L2− or L4−). Dogs vaccinated correctly or partially
with L4 were considered L4+ or L4−, respectively, even if they
previously had been vaccinated correctly with L2. Dogs never vac-
cinated with any antileptospiral vaccine (L2 or L4) were classified
as L0.
For the analysis related to the L4 vaccination status, all dogs were
classified as L0, L4−, or L4+. Similarly, for the analyses related specifi-
cally to the L2 vaccination status, all dogs never vaccinated with L4
were classified as L0, L2−, or L2+.
Dogs correctly vaccinated with either L2 or L4 and diagnosed
with acute leptospirosis were classified as cases of leptospirosis in L2
or L4 vaccinated dogs, respectively. Age, diagnostic criteria, seroposi-
tivity rates, and time from last vaccination were reviewed separately
for these cases of particular interest in the context of vaccine
protection.
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2.7 | Statistical analysis
General: Sample size calculations and data analyses were performed
using commercial software programs (PASS 13 Power Analysis and
Sample Size Software, 2014 and NCSS 9 Statistical Software, 2013;
NCSS, LLC. Kaysville, Utah, respectively).
The continuous variables age and time from vaccination were
tested for normality by visual inspection of histograms and a Shapiro
Wilk test, both for all dogs with AKI and for the subgroups, when
applicable. Because they were not normally distributed, their descrip-
tive statistics were reported as median (interquartile range, IQR) and
they were compared among groups using a Kruskal-Wallis one-way
analysis of variance (ANOVA). Categorical variables were reported as
absolute numbers and proportions, and were compared among groups
using a chi-square test or a Fisher's exact test when the expected
counts were <5 in a cell from the contingency tables. They included
variables compared among time periods (PRE, TRANS, POST): diagno-
sis, availability of complete vaccination information, presence of ade-
quate vaccination status (L2, L4, or any L-vaccine), and MAT
seropositivity for 13 individual serovars. Variables compared among
the categories of vaccination status (L0, L4−, L4+) were: sex, neuter
status, and breed groups, and variables compared between the 2 dis-
ease groups (AKI-L, AKI-nL) were: sex (male, female), neuter status
(intact, neutered), breed group (herding, hound, nonsporting, sporting,
terrier, toy, working, and mixed breed), organ manifestations (hepatic,
hemostatic, pulmonary), vaccine use (L0, L2, L4), and vaccination sta-
tus (L0, L2−, L2+, L4−, L4+; adequate status for any L-vaccine;
adequate protection for 2 serogroups; adequate protection for
4 serogroups). Unless mentioned otherwise, a P-value of .05 was used
as cut-off for statistical significance.
Descriptive section: Average annual case numbers, vaccine use,
and vaccination status were calculated for both disease groups for the
3 study periods: PRE, 2011-2012; TRANS, 2013-2014; POST,
2015-2017. Yearly case numbers were calculated based on the total
population of dogs diagnosed with AKI-L and AKI-nL, independently
of whether vaccination information was available or not. Vaccine use,
vaccination status, and associations between vaccination and disease
were assessed in the subpopulation of dogs with known vaccine
information.
Analytical section: The association between vaccination status
and diagnosis of leptospirosis was evaluated using multivariable logis-
tic regression analysis as the odds ratio (OR) for a dog with AKI to be
diagnosed with AKI-L vs AKI-nL, if correctly vaccinated (L2+, L4+) or
partially vaccinated (L2−, L4−) vs not vaccinated (L0 as reference).15
Separate analyses were performed for L2 and L4 vaccination status,
because too many combinations and therefore subgroups would have
been necessary to cover all possible status variations with a single
model. Because of common changes among different brands of L2
used within individual dogs, the effect of L2 was not evaluated at the
brand level but as a group effect. Assuming that antileptospiral vacci-
nation neither caused nor protected from AKI-nL, this OR can be
viewed as an estimation of the association of vaccination with
disease.16
An estimation of the sample size necessary for the planned
analyses was performed with the following variables and assump-
tions, based on a preliminary evaluation at our institution: L4 vac-
cination status (L4+, L4−, L0 [reference]) as independent variable;
diagnosis (AKI-L, AKI-nL [reference]) as binary dependent variable;
assumption of a change in the probability for a dog with AKI to be
diagnosed with AKI-L from 75% when not vaccinated (estimated
from the hospital population, 2011-2012) to <33% when vacci-
nated with L4 (estimated from the hospital population,
2015-2017); proportion of dogs current on their antileptospiral
vaccination 50%; power 0.9 and alpha 0.05. This analysis yielded a
minimal number of 54 dogs with AKI necessary for univariable
logistic regression analysis. The addition of confounders with low
correlation to the independent variable in a multivariable logistic
regression model would require 109 dogs with AKI.
A similar estimation was performed for L2 vaccination status,
using the assumption that a change in the proportion of AKI diagnosis
from 75% when not vaccinated (estimated from the hospital popula-
tion, 2011-2012) to 50% for AKI-L (a decrease of at least 33% was
considered arbitrarily to be necessary to be considered clinically rele-
vant), when correctly vaccinated with L2, should be recognized. It
yielded a minimum number of 153 dogs with AKI for univariable anal-
ysis and 306 dogs with AKI when confounders were included in a mul-
tivariable logistic regression model.
Sex, neuter status and breed group have been reported to be
associated with both the independent and the dependent vari-
ables.4,17-19 They therefore were assessed as potential
F IGURE 1 Yearly incidence of diagnosis of leptospirosis (AKI-L)
and of AKI not caused by leptospirosis (AKI-nL) during the 7 years of
the study spanning before and after the introduction of the new L4
vaccine in 2013
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confounders by evaluating their statistical associations with both
the independent and dependent variables: sex (female vs male),
neuter status (neutered vs intact), breed group (herding, hound,
nonsporting, sporting, terrier, toy, working, and mixed breed), and
age (as a continuous variable). Variables with P values <.10
(Kruskal-Wallis or chi-square test) were considered potentially
associated with the independent, dependent or both variables and
were included as potential confounders in the multivariable analy-
sis. These variables were added 1-by-1 in the multivariable logistic
regression model (log[OR] = β1 + β2 * [vaccination status]
+ βi * [confounderi], including interactions), based on their log-like-
lihood, using a forward variable selection approach.15 Variables
were included until the addition of further variables did not result
in a better-fit model, indicated by a lack of a further decrease of
the Akaike Information Criterion (AIC) value. The following diag-
nostics were conducted on the obtained logistic regression
models: continuous variables of the models were evaluated for lin-
earity by visual evaluation of the plot of their relationship with the
logit of outcome; the included variables and their interactions
were evaluated by introducing them in the models and checking
their effect on the regression coefficient β of the remaining vari-
ables (a change >20% was considered significant to keep them in
the model); the model fit was assessed using the Pearson chi-
square goodness-of-fit statistic and outliers were identified by
analyzing the Pearson residuals (<−2 or >2). The percentage of
correct predictions and the area under the receiver operating char-
acteristic curve (ROC-AUC) were calculated as additional indica-
tors of model performance.
To minimize potential misclassification bias, both logistic regres-
sion analyses were repeated using a restricted case definition after
excluding cases and controls diagnosed based on clinical evidence
only (1e, 1f, 2d).
TABLE 1 Number of cases, demographics, main disease characteristics, and basis for diagnosis of 469 dogs with AKI due to leptospirosis
(AKI-L) or other causes (AKI-nL)
AKI-L AKI-nL
All dogs with diagnosis 269 200
Dogs with complete vaccination history (% of all dogs) 223 (83%) 145 (73%)
Number of cases (average per year)
PRE (2011-2012) 56.5 16.5
TRANS (2013-2014) 54.5 26.5
POST (2015-2017) 15.7 38.0
Sex
Female [intact/spayed] 92 (34%) [32/60] 79 (40%) [22/57]
Male [intact/castrated] 177 (66%) [114/63] 121 (61%) [65/56]
Age (y) (median, IQR) 5.9 (1.8-8.7) 7.3 (4.1-10.6)
Main organ manifestations
Renal 269 (100%) 200 (100%)
Hepatic 102 (38%) 37 (19%)
Pulmonary 165 (61%) 16 (8%)
Hemorrhagic 106 (39%) 56 (28%)
Basis for diagnosis
PCR (1a) 6 (2%)
MAT seroconversion (1b) 123 (46%)
Single MAT (1c) 81 (31%)
Rapid test (1d) 25 (9%)
Strong clinical evidence (1e) 26 (10%)
Suggestive clinical evidence (1f) 8 (3%)
Established diagnosis (2a) 156 (78%)
Suspected diagnosis + MAT 2× neg (2b) 13 (7%)
Suspected diagnosis + MAT 1× neg (2c) 81 (31%)
No evidence of leptospirosis (2d) 14 (7%)
Abbreviations: AKI, acute kidney injury; IQR, interquartile range; L, leptospirosis; MAT, microscopic agglutination test; MAT 2x neg, negative paired MAT
serology; MAT 1× neg, 1 negative MAT serology; nL, nonleptospirosis; PRE, period before the introduction of L4; POST, period after the introduction of
L4; PCR, polymerase chain reaction; TRANS, transition period.
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3 | RESULTS
3.1 | Dogs and diseases
During the study period from 2011 to 2017, 469 dogs were diag-
nosed with AKI-L (n = 269) or AKI-nL (n = 200). Complete vaccina-
tion information was available for 368 dogs (78%): 223 dogs with
AKI-L (83%) and 145 dogs with AKI-nL (73%). The proportion of
dogs with complete vaccination information was higher in dogs
with AKI-L than in those with AKI-nL (P = .007), but unchanged
among the 3 time periods (PRE, 79%; TRANS, 77%; POST, 80%;
P = .92). The numbers of dogs with a diagnosis of AKI-L and AKI-
nL included for each year of the study are shown in Figure 1. Of
these, 115 dogs were available with complete vaccination informa-
tion in time period PRE (97, AKI-L; 18, AKI-nL), 125 in time period
TRANS (87, AKI-L; 38, AKI-nL), and 128 in time period POST
(39, AKI-L; 89, AKI-nL). The demographics and main disease char-
acteristics of both study groups are summarized in Table 1. The
average number of dogs diagnosed with AKI-L was significantly
lower in the POST period than in earlier time periods (P < .0001)
and the number of dogs with AKI-nL was significantly higher in the
POST period than in earlier time periods (P < .0001).
The basis for the diagnosis of dogs as AKI-L and AKI-nL is
described in Table 1. The repartition of the categories was almost
identical in the subgroup of 223 dogs with available vaccine informa-
tion as for the whole group. Seropositivity with a MAT titer ≥1:800
was detected for the following serovars: Australis (73%), Bratislava
(64%), Copenhageni (29%), Pomona (28%), Autumnalis (26%),
Grippotyphosa (15%), Canicola (9%), Icterohaemorrhagiae (5%),
Pyrogenes (1%), and Bataviae (1%). The prevalence of seropositivity
TABLE 2 Vaccine use and vaccination status in dogs with AKI due to leptospirosis (AKI-L) or other causes (AKI-nL)
AKI-L (n = 223) AKI-nL (n = 145) P (L vs nL)
Vaccine use at the time of disease
L0 10 (4%) 4 (3%) .4
L2 190 (85%) 69 (48%) <.001
L4 23 (10%) 72 (50%) <.001
Vaccination status
L0 10 (4%) 4 (3%) .4
L2− 62 (28%) 36 (25%) .53
L2+ 128 (57%) 33 (23%) <.001
L4− 8 (4%)a 32 (22%)b <.001
L4+ 15 (7%) 40 (28%) <.001
Current protection for 2 SG at the time of diagnosisc 147 (66%)
PRE 75/97 (77%)
TRANS 56/87 (64%)
POST 16/39 (41%)
87 (60%)
PRE 11/18 (61%)
TRANS 21/38 (55%)
POST 55/89 (62%)
.2
Current protection for 4 SG at the time of diagnosisd 15 (7%)
PRE 0/97 (0%)
TRANS 5/87 (6%)
POST 10/39 (26%)
40 (28%)
PRE 0/18 (0%)
TRANS 4/38 (11%)
POST 36/89 (40%)
< .001
Partial protection for 2 SG at the time of diagnosisc 66 (30%)
PRE 21/97 (22%)
TRANS 26/87 (30%)
POST 19/39 (49%)
54 (37%)
PRE 7/18 (39%)
TRANS 17/38 (45%)
POST 30/89 (34%)
= .13
Partial protection for 4 SG at the time of diagnosisd 8 (4%)
PRE 0/97 (0%)
TRANS 2/87 (2%)
POST 6/39 (15%)
32 (22%)
PRE 0/18 (0%)
TRANS 6/38 (16%)
POST 26/89 (29%)
< .001
Note: P refers to the statistical significance of the comparisons of proportions between the groups L and nL, using a chi-square test. The comparisons in
the lower part of the table refer only to the proportions calculated for the whole study and not for the individual time periods.
Abbreviations: AKI, acute kidney injury; L, leptospirosis; nL, nonleptospirosis; L0, never vaccinated with an antileptospiral vaccine; L2, bivalent vaccine; L4,
quadrivalent vaccine; L2−, vaccinated with L2 but not current on L2; L2+ current on L2; L4−, vaccinated with L4 but not current on L4; L4+ current on L4;
PRE, period before the introduction of L4; POST, period after the introduction of L4; SG, serogroup.
a4 of these 8 AKI-L dogs (L4−) had ongoing appropriate protection for the 2 serogroups Canicola and Icterohaemorrhagiae, as the L2 vaccine was just rep-
laced with L4 without new primo-vaccination.
b14 of these 32 AKI-nL dogs (L4−) had ongoing appropriate protection for the 2 serogroups Canicola and Icterohaemorrhagiae, as the L2 vaccine was just
replaced with L4 without new primo-vaccination.
cSerogroups Canicola and Icterohaemorrhagiae.
dSerogroups Canicola, Icterohaemorrhagiae, Australis, and Grippotyphosa.
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increased significantly over time for serovar Bratislava (54% PRE to
77% POST, P = .01), with no change for the other serovars.
Diagnoses identified in the group AKI-nL included toxicoses
(n = 49, 25%), infections (n = 27, 14%), inflammatory diseases
(n = 11, 6%), hemodynamic disturbances (n = 14, 7%), mul-
tisystemic diseases (n = 70, 35%), acute-on-chronic kidney decom-
pensation (n = 11, 6%), upper urinary tract obstruction (n = 2, 1%),
and unclear etiology (n = 16, 8%). Leptospira seropositivity with a
MAT titer ≥1:800 was not observed in dogs with AKI-nL. Using a
lower cutoff of 1:100, seropositivity in these dogs was detected
for the following serovars: Canicola (12%), Copenhageni (8%), Aus-
tralis (6%), Grippotyphosa (4%), Bratislava (3%), Pomona (3%), and
Icterohaemorrhagiae (3%). No obvious difference was noted
between vaccinated and nonvaccinated dogs for the
corresponding serovars, but no statistical comparison was per-
formed because of the low number of dogs in some groups. Dogs
with AKI-nL were significantly less likely to have hepatic
(P < .0001), hemorrhagic (P = .01) or pulmonary (P < .0001)
involvement than were dogs with AKI-L.
3.2 | Vaccine use and vaccination status
Data on vaccine use and vaccination status are summarized in
Table 2, and changes over time are represented in Figures 2 and 3.
The proportion of the control AKI-nL dogs never vaccinated remained
low throughout the study (0/18 PRE, 0/38 TRANS, and 4/89 POST).
The partial immunization status for L4 observed in 32 dogs was
because of incorrect primary vaccination (n = 25), incorrect yearly
booster schedule (n = 7), or a last vaccine administration >365 d
before presentation for AKI (n = 14); >1 condition was not fulfilled in
10 dogs.
3.3 | Logistic regression analysis
Based on sample size analysis, the study population of 368 dogs with
complete vaccination information was considered sufficient to
address the study aims, including the evaluation of confounder vari-
ables. The following variables were evaluated as potential
F IGURE 2 Change in vaccine use
in 368 dogs with AKI (left panel),
including 223 dogs with AKI-L (top
right panel) and 145 dogs with AKI-nL
(low right panel). Dogs were classified
as nonvaccinated (L0), vaccinated
with L2, or vaccinated with L4, and
grouped according to the 3 time
periods of the study
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confounders for the logistic regression analysis: sex, neuter status,
breed group, and age (Tables 3 and 4). Sex and breed group were elim-
inated because they were not associated with both the independent
and dependent variables. Neuter status was associated with the
dependent variable and age with both the independent and depen-
dent variables. They both were included in the multivariable models.
In the L4 multivariable analysis, vaccination status and age were
strongly associated with diagnosis (Table 5). Vaccinated dogs and
older dogs were at lower odds to be diagnosed with leptospirosis than
were nonvaccinated or younger dogs, respectively. The OR for a dog
presented with AKI to be diagnosed with AKI-L vs AKI-nL was 0.112
(95% CI, 0.056-0.222; P < .001) when correctly vaccinated with L4
(L4+) and 0.090 (0.039-0.211; P < .001) when partially vaccinated
with L4 (L4−). In the L2 multivariable analysis, only age and neuter
status were significantly associated with the diagnosis but not L2 vac-
cination status (Table 5). The OR for a dog presented with AKI to be
diagnosed with AKI-L vs AKI-nL was 2.078 (0.582-7.419; P = .26)
when correctly vaccinated with L2 (L2+) and 1.037 (0.286-3.757;
P = .96) when partially vaccinated with L2 (L2−). Diagnostics con-
ducted on both models are reported in Table 5.
The analyses based on the more restrictive case definition
included 333 dogs for L4 (198 AKI-L; 135 AKI-nL) and 244 dogs for
L2 (179 AKI-L; 65 AKI-nL). They gave very similar results as the
models including all dogs with vaccination information (Table S1,
Supporting Information). The L4 model indicated ORs of 0.081
(0.038-0.174; P < .001) for L4+ and 0.091 (0.038-0.214; P < .001) for
L4−. The L2 model indicated ORs of 2.215 (0.610-8.046; P = .23) for
L2+ and 1.044 (0.285-3.832; P = .95) for L2−. Both models included
age and neuter status as significant covariates.
3.4 | Leptospirosis in vaccinated dogs
During the 7 years of the study (PRE, TRANS, POST), 128 cases of
leptospirosis in L2-vaccinated dogs were observed. Median age of the
affected dogs was 5.8 years (IQR, 1.2-8.8; range, 0.2-15.3). All dogs
had received a correct vaccination schedule. Median time from the
last vaccination to the first signs of disease was 181 days (IQR,
76-296; Figure 4), with no obvious clustering of cases in any of the
postvaccination time periods. Seropositivity rates (MAT titer ≥1:800)
F IGURE 3 Vaccination status of
368 dogs with AKI (left panel),
including 223 dogs with AKI-L (top
right panel) and 145 dogs with AKI-nL
(low right panel). Dogs were classified
as nonvaccinated (L0), correctly
vaccinated with L2 (L2+),
inadequately vaccinated with L2 (L2
−), correctly vaccinated with L4 (L4+),
or inadequately vaccinated with L4
(L4−), and they were grouped
according to the 3 time periods of the
study
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TABLE 3 Descriptive statistics of the
variables evaluated as potential
confounders for the logistic regression
analysis evaluating the association of L4
vaccination status and a diagnosis of
leptospirosis
AKI-L (N = 223) AKI-nL (N = 145) P
Age (years) [median, IQR] 5.7 (1.6-8.7) 7.5 (4.1-10.8) <.001
Sex
Female 75 (34%) 54 (37%) .48
Male 148 (66%) 91 (63%)
Neuter status
Intact 123 (55%) 64 (44%) .04
Neutered 100 (45%) 81 (56%)
Breed group .6
Herding 30 (13%) 25 (17%)
Hound 11 (5%) 5 (3%)
Nonsporting 13 (6%) 11 (8%)
Sporting 68 (30%) 34 (23%)
Terrier 21 (9%) 9 (6%)
Toy 21 (9%) 15 (10%)
Working 28 (13%) 20 (14%)
Mixed breed 31 (14%) 26 (18%)
Note: The 368 dogs diagnosed with AKI for which complete vaccination information was available were
stratified based on their diagnosis. P refers to the statistical significance of a Kruskal-Wallis one-way
ANOVA (continuous variable: age) or of the chi-square test (categorical variables: sex, neuter status,
breed group).
Abbreviations: AKI-L, acute kidney injury due to leptospirosis; AKI-nL, acute kidney injury from other cau-
ses than leptospirosis; IQR, interquartile range.
TABLE 4 Descriptive statistics of the
variables evaluated as potential
confounders for the logistic regression
analysis evaluating the association of the
L4 vaccination status with a diagnosis of
leptospirosis
L0 (N = 55) L4− (N = 40) L4+ (N = 273) P
Age (years) [median, IQR] 6.4 (2.5-9.1) 7.7 (3.5-11.3) 5.9 (1.6-8.9) .09
Sex
Female 94 (34%) 17 (43%) 18 (33%) .56
Male 179 (66%) 23 (58%) 37 (67%)
Neuter status
Intact 139 (51%) 20 (50%) 28 (51%) .99
Neutered 134 (49%) 20 (50%) 27 (49%)
Breed group .95
Herding 40 (15%) 8 (20%) 7 (13%)
Hound 11 (4%) 1 (3%) 4 (7%)
Nonsporting 18 (7%) 3 (8%) 3 (5%)
Sporting 77 (28%) 9 (23%) 16 (29%)
Terrier 23 (8%) 4 (10%) 3 (5%)
Toy 29 (11%) 4 (10%) 3 (5%)
Working 34 (12%) 4 (10%) 10 (18%)
Mixed breed 41 (15%) 7 (18%) 9 (16%)
Note: The 368 dogs diagnosed with AKI for which complete vaccination information was available were
stratified based on their L4-vaccination status. P refers to the statistical significance of the Kruskal-Wallis
one-way ANOVA (continuous variable: age) or of the chi-square test (categorical variables: sex, neuter
status, breed group).
Abbreviations: L0, not vaccinated with L4; L4−, partially vaccinated with L4; L4+, correctly vaccinated
with L4; IQR, interquartile range.
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were similar in correctly and incorrectly L2-vaccinated dogs with
AKI-L: Australis (75%/73%), Bratislava (62%/71%), Copenhageni
(22%/32%), Pomona (27% / 31%), Autumnalis (25%/29%),
Grippotyphosa (19%/13%), Canicola (12%/7%), Icterohaemorrhagiae
(5%/7%), Pyrogenes (1%/2%), and Bataviae (1%/1%).
During the last 5 years of the study (TRANS, POST), 15 cases of
leptospirosis in L4-vaccinated dogs were observed. Median age of the
affected dogs was 1.1 years (IQR, 0.7-2.8; range, 0.4-13.6). All dogs
had received a correct vaccination schedule. Thirteen dogs were
affected within 1 year of the end of the initial primary vaccination and
2 dogs had received 1 booster vaccine afterward. Time from last vac-
cination to first clinical signs was a median of 165 days (IQR, 86-252;
Figure 4), with no obvious clustering of cases in any of the time
periods. The diagnosis of leptospirosis was confirmed based on MAT
seroconversion in 7 dogs (1b), a single positive MAT titer in 3 dogs
(1c), a positive IgM lateral flow assay in 1 dog (1d), and strongly sug-
gestive clinical signs with 3 of the 4 classical manifestations of lepto-
spirosis in 4 dogs (1e). The prevalence of seropositivity for the
13 dogs with available serology was similar to other dogs with AKI-L:
Australis (77%), Bratislava (69%), Grippotyphosa and Autumnalis
(23%), Pomona (15%), Copenhageni (25%), and Bataviae and Hardjo
(8%). These dogs were similarly affected clinically as were other dogs
with AKI-L, including renal (n = 15, 100%), hepatic (n = 4, 27%), hem-
orrhagic (n = 5, 33%) and pulmonary (n = 9, 60%) manifestations.
During the last 5 years of the study (TRANS, POST), another
8 dogs not properly vaccinated with L4 were diagnosed with leptospi-
rosis. The initial vaccination had not been performed correctly in
5 dogs (including 2 dogs missing the second injection because of
AKI-L and 3 dogs receiving only 1 injection), yearly boosters had been
missed in 2 dogs, and the last vaccine administration was >365 days
before presentation in 1 dog.
4 | DISCUSSION
Between 2003 and 2012, Switzerland has experienced a steep
increase in the incidence of acute leptospirosis in dogs, reaching epi-
demic proportions with a peak of 28.1 confirmed cases of severe dis-
ease per 100 000 dogs/year in the most affected area.4 During that
time, infections in dogs were most commonly associated with sero-
group Australis, suggesting that the then available bivalent anti-
leptospiral vaccine did not confer sufficient protection against
infection with this serogroup. In 2013, a new quadrivalent anti-
leptospiral vaccine, including serogroups Australis and Grippotyphosa
TABLE 5 Results of the multivariable
logistic regression analyses for
associations with a diagnosis of AKI-L vs
AKI-nL as dependent variable
Variable (reference) β SE OR 95% CI of OR Wald-P
L4-vaccination model
Intercept 1.70 0.28 5.493 3.175-9.506 <.001
L4-vaccination status (L0)
L4+ −2.19 0.35 0.112 0.056-0.222 <.001
L4− −2.40 0.43 0.090 0.039-0.211 <.001
Age −0.13 0.03 0.877 0.824-0.934 <.001
Neuter status (intact)
Neutered −0.48 0.25 0.619 0.381-1.005 .05
73.4% dogs classified correctly; ROC-AUC, 0.774
Pearson chi-square 69.1; 12 outliers on Pearson residual analysis
Variable (reference) β SE OR 95% CI of OR Wald-P
L2-vaccination model
Intercept 0.72 0.64 2.046 0.588-7.120 .26
L2-vaccination status (L0)
L2+ 0.73 0.65 2.078 0.582-7.419 .26
L2− 0.04 0.66 1.037 0.286-3.757 .96
Age −0.10 0.04 0.905 0.839-0.976 .009
Neuter status (intact)
Neutered −0.85 0.29 0.426 0.239-0.759 .004
61.2% dogs correctly classified; ROC-AUC, 0.690
Pearson chi-square 119.3; 1 outlier on Pearson residual analysis
Note: These analyses include all 368 dogs with complete vaccination information for the L4 model and
273 dogs for the L2 model. Additional diagnostics conducted on both models include the linearity check
for the continuous variable age. The variable checks confirmed the inclusion of the model variables
except for the L2-vaccination status in the L2-model; none of the variable interactions was retained.
Abbreviations: β, regression coefficient; OR, odds ratio; 95% CI, 95% confidence interval; ROC-AUC, area
under the curve of the receiver operating characteristic curve.
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in addition to serogroups Canicola and Icterohaemorrhagiae was
introduced to the Swiss market.12 The rapid increase in use of the L4
vaccine observed in our control group likely mirrors the uptake of the
vaccine in the general dog population in Switzerland. This probably
reflects the expectation of well-informed owners and of veterinarians
confronted with the clinical challenges of severe leptospirosis, hoping
that the new quadrivalent vaccine would fill the protection gap left by
the former bivalent vaccines.4 Interestingly, despite motivation to
change vaccine type in 70% of the control dogs, only 40% of the con-
trols were correctly vaccinated with L4 in the POST period, emphasiz-
ing continued need for veterinarian and owner education.
The number of cases of leptospirosis diagnosed at the Vetsuisse
Faculty University of Bern decreased rapidly and sustainably from
2015 onwards whereas the number of dogs with AKI-nL increased
throughout the study period. This development shows that the
decrease in leptospirosis cases was not because of a decreased
nephrology caseload, but because of a selective decrease in cases of
leptospirosis, indicating either a true decrease in the number of cases
or a decrease in disease severity, no longer requiring specialized hos-
pital care. At the same time, not only vaccine use but also actual vacci-
nation status of the dogs included in the study changed from a
bivalent to a predominantly quadrivalent vaccination, whereas the
proportion of unvaccinated or incompletely vaccinated dogs remained
stable over time. Because previously observed fluctuations in the
number of cases of leptospirosis4 never reached this magnitude and
were never sustained over 1 year, it is possible that the observed
decrease in cases of leptospirosis in dogs is linked to the introduction
of L4, although changes in the biology of the environment, in the
disease pressure, or in the risk of pathogen exposure cannot be
ruled out.
The timely association between introduction of the new vac-
cine and the marked decrease in disease incidence is particularly
striking, considering that only 40% of the dogs were correctly
immunized. Whether this outcome can be explained by apparent
protection despite incomplete L4 vaccination, as suggested by
these results, should be verified because of the very small size of
some of the subgroups, especially the L4− dogs diagnosed with
AKI-L.
Lack of a mandatory national disease registry limits ability to eval-
uate major epidemiological changes for diseases such as leptospirosis
and broad-scale interventions such as vaccinations. Previous studies
have reported the change in disease incidence associated with vacci-
nation for various diseases in dogs, including rabies and leptospiro-
sis.20,21 However, ours is to the best of our knowledge among the few
reports also documenting the detailed vaccination status of the
affected and control dogs, and testing its association with the diagno-
sis. To do so, we chose a retrospective case-control study design,
based on a referral population from a single hospital, using dogs with
AKI not caused by leptospirosis as controls. This very specific refer-
ence population only partially represents the general dog population
in terms of vaccine use and vaccination status, and it is likely over-
represented by dogs from very motivated owners, ready to be
referred and treated at a specialized institution. However, it is proba-
bly the most adequate control group for dogs with leptospirosis in
terms of referral bias. Because >99% of dogs with leptospirosis in
Switzerland are presented with AKI,4 most dogs ultimately diagnosed
with leptospirosis were referred for evaluation and treatment of this
condition. The differentiation between AKI-L and AKI-nL was in most
cases established during diagnostic evaluation after referral.
The odds of a dog presented with AKI to be diagnosed with lepto-
spirosis were 8.9 (when including all dogs) to 12.3 (with a more
restrictive case definition) times lower when vaccinated with L4 than
when not vaccinated. This is in sharp contrast to the absence of asso-
ciation observed with L2 vaccination. These results suggest that vacci-
nation with L4 in the epidemiological context of Switzerland may be a
protective factor against the disease. The retrospective case-control
study design does not however prove a causal relationship, and it is
limited to documenting an association. For rare diseases such as lepto-
spirosis however, a prospective vaccine effectiveness study under
field conditions would require a very large group of dogs and long-
term observation. Typical experimental models on the other hand fail
to reproduce relevant aspects of the naturally occurring disease,
including the presence of undetected conditions at the time of vacci-
nation, a wide range of ages, the presence of various comorbidities,
and possible exposure to leptospires in the environment.
Because only 1 quadrivalent antileptospiral vaccine (Nobivac
Lepto 6, MSD Animal Health) was licensed on the Swiss market until
mid-2017, all study dogs vaccinated with L4 were vaccinated with this
specific vaccine. Although newer quadrivalent vaccines show a similar
serogroup profile, the vaccinal serovars and strains are different, and
F IGURE 4 Time between the last antileptospiral vaccine
administration and the first signs of leptospirosis in dogs correctly
vaccinated with L2 (n = 128 dogs) or L4 (n = 15 dogs)
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extrapolation to other vaccines cannot be made based on the
available data.
The numerous cases of leptospirosis in L2-vaccinated dogs were
probably caused mostly by a mismatch between vaccine and infecting
serogroups,11 although the identity of the true infecting serogroups in
Switzerland has not been confirmed yet. The epidemiological data still
rely mostly on serological evidence and not on identification of the
infecting serovar after isolation from clinical cases.4,22,23 The absence
of an obvious clustering of cases in any of the time periods post-
vaccination (Figure 4) suggests that these cases were not associated
with an insufficient duration of vaccine protection. The cases of lepto-
spirosis in L4-vaccinated dogs also could reflect a partial mismatch
between vaccine and infecting strains, a broader range of infecting
serogroups than previously observed and suspected, or health factors
negatively influencing the protective immune response of the dogs at
the time of vaccination. Further technical variables including inappro-
priate injection technique and vaccine distribution and storage can
never be ruled out in a retrospective clinical study. The similarities in
the disease manifestations, their severity, and the suspected
serogroups implied in the cases of leptospirosis in L4-vaccinated dogs
compared to the other dogs with leptospirosis suggest that these dogs
did not develop a milder or different form of disease but behaved
mostly like unvaccinated dogs. Currently, no evidence exists for the
re-emergence of newer leptospiral serovars not covered by the vac-
cine, although this cannot be excluded because serological results only
poorly represent the true infecting serovar.24 Because 87% of the
cases of leptospirosis in L4-vaccinated dogs were observed during the
year after initial vaccination, inactivation of vaccine antigens by
maternal antibodies and insufficient vaccine response cannot be
excluded in some dogs, possibly warranting a modification of the ini-
tial vaccination recommendations. Any such change should however
first be evaluated in a specifically designed prospective study because
the proportion of dogs in the first year of vaccination is disproportion-
ately high in the first years after the introduction of a new vaccine
and could bias these results.
One important limitation of our study is its retrospective nature
with inherent lack of a standardized diagnostic approach and the risk
of preferentially selecting severely affected cases. The use of a refer-
ral population from a teaching hospital may further limit the applicabil-
ity of results to the general dog population by selecting cases on the
willingness of their owners to pursue more advanced diagnostic and
treatment options. However, the inclusion of a control group with
similar presentation and severity of disease and the systematic use of
established diagnostic protocols should have decreased these risks
and affected both groups similarly, therefore minimizing their effect
on the respective incidences of infection in the groups. The applicabil-
ity of these results to milder or subclinical forms of leptospirosis
should be evaluated in separate studies.
The choice of a control population very similar to the case popu-
lation in terms of clinical presentation and disease severity may fur-
ther limit the generalizability of the findings to the general dog
population of interest. However, this choice also may limit the impact
of missed confounders, because these would be more likely to affect
similar groups in the same way and therefore have less influence on
the conclusions of the study. Because antileptospiral vaccines confer
mostly serogroup-specific protection,10,11 the efficacy of this vaccine
may vary considerably between regions depending on the prevailing
serogroups. It therefore remains important to monitor the regional
epidemiology of leptospirosis in dogs and adapt strategies
accordingly.
The small size of some of the subgroups may have limited the
power of the statistical analyses, but this limitation should be placed
in the context of the actual prevalence of the disease. Our study
includes 1 of the largest groups of well-characterized dogs with lepto-
spirosis and a control group of dogs with AKI matched in terms of dis-
ease severity. Misclassification bias cannot be ruled out, especially in
the absence of a systematic diagnostic evaluation with paired MAT
serology and PCR in all dogs and with changes in the availability and
selection of diagnostic tests over time. However, the extensive and
individualized diagnostic evaluation performed in these dogs is
expected to have minimized this bias. The use of MAT serology as a
central diagnostic tool has only a limited capability for the diagnosis of
the infecting serovars in the individual dog.24 However, it remains the
main tool available for the confirmation of leptospirosis in dogs in a
clinical setting.23 Its very good performance for the diagnosis of the
disease, rather than for definition of the infecting serovar, suggests
that the limitations of this test are unlikely to have significantly
affected the results of our study.
In conclusion, being vaccinated with L4 was strongly associated
with decreased odds to be diagnosed with leptospirosis compared
to unvaccinated dogs, suggesting a protective effect against the
disease. This finding is in contrast to the lack of association
observed for L2-vaccinated dogs. Considering the level of evidence
available at this time, results of our study support use of quadriva-
lent antileptospiral vaccines as core vaccines for dogs living in areas
with a high incidence of leptospirosis caused by the included
serogroups.
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